Symbols

Symbols

FBIO

FBIO

Fortress Biotech Q3 Revenue Increases 20.5% Amid $28 Million Checkpoint Sale

Fortress Biotech Q3 rev up 20.5% to $17.6mln, Checkpoint Therapeutics acquired.

Thursday Oct 23, 2025

Pomerantz LLP investigates Fortress Biotech securities fraud claims.

Tuesday Oct 21, 2025

TZ Rejects Non-Binding Offer for US Unit Telezygology

Urica Therapeutics Subsidiary Crystalys Doses First Patients in Phase 3 Gout Trials

Wednesday Oct 15, 2025

Fortress Biotech Pref A: MACD Death Cross, Bollinger Bands Narrowing, KDJ Death Cross

Tuesday Oct 14, 2025

Fortress Biotech Pref A's 15min chart shows RSI oversold, KDJ golden cross.

Tuesday Oct 07, 2025

Fortress Biotech Pref A's KDJ Death Cross indicates bearish sentiment.

Monday Oct 06, 2025

Fortress Biotech Pref A's 15min chart triggered Bollinger Bands Narrowing,KDJ Death Cross,Bearish Marubozu

Fortress Biotech Pref A's 15min chart triggers KDJ Golden Cross, bullish Marubozu signal.

Friday Oct 03, 2025

Fortress Biotech Pref A's 15min chart triggers MACD Death Cross, KDJ Death Cross

Fortress Biotech Pref A: KDJ Golden Cross, Bullish Marubozu in 15-Minute Chart

Fortress Biotech Pref A's 15min chart shows Bollinger Bands Narrowing, Bearish Marubozu.

Fortress Biotech Pref A's 15min chart shows RSI Overbought and Narrowing Bollinger Bands.

Wednesday Oct 01, 2025

Fortress Biotech Faces FDA Setback on Menkes Disease Treatment: CUTX-101's Approval Hinges on Addressing Manufacturing Deficiencies

Fortress Biotech to Benefit from Crystalys' $205M Funding for Gout Treatment

Fortress Biotech Pref A's chart exhibits Bollinger Bands narrowing and bearish Marubozu pattern.

Fortress Biotech Shares Plunge 31% as FDA Rejects Rare Disease Drug CUTX-101

BizCare Benefits and PrismHR Partner to Offer Affordable and Flexible ICHRA Plans

Fortress Bio and Zydus' Rare Pediatric Treatment Denied FDA Approval